The results highlighted the potential of targeting endoplasmic reticulum (ER), oxidation, actin cytoskeleton and mitosis in prostate cancer management, and further validation identified AIM1 (absent in melanoma 1), ERGIC1 (endoplasmic reticulum-Golgi intermediate compartment protein 1), TMED3 (transmembrane emp24 protein transport domain containing 3) and TPX2 (targeting protein for Xklp2) as potential novel drug targets in prostate cancer. Here, ERGIC1 is linked to prostate carcinoma.